<DOC>
	<DOCNO>NCT02377674</DOCNO>
	<brief_summary>The extracardiac Fontan surgery/procedure involve divert venous blood inferior vena cava pulmonary artery without pass morphologic right ventricle . In extracardiac conduit type Fontan , one end synthetic tube graft connect inferior vena cava end pulmonary artery confluence . Xeltis develop biodegradable prosthesis , Xeltis Vascular Graft Model COR-VG-001 , use extracardiac conduit right atrium pulmonary artery . The prosthesis immediately mechanically functional , physiochemical characteristic enable cell infiltration tissue formation . The Xeltis Vascular Graft Model COR-VG-OO specifically design enhance Fontan surgery outcome reduce synthetic material relate complication improve hemodynamic characteristic .</brief_summary>
	<brief_title>Safety Performance COR-VG-001 Conduit Pediatric Patients Extracardiac Total Cavopulmonary Connection</brief_title>
	<detailed_description>Although significant progress make recent year field congenital heart disease treatment , substantial unmet clinical need remain implantable materials/devices vascular graft heart valves improved long-term performance reduce device-related complication . To address limitation new generation biodegradable polymer use recent advance supramolecular chemistry develop create highly porous vascular graft allow efficient cell infiltration follow gradual replacement polymer material patient 's native-like vascular tissue result full functional restoration . In addition ability reduce postoperative graft-related complication type implant potential grow adapt overall body growth therefore may represent completely new modality treatment congenital heart disease . In contrast today 's situation synthetic non-absorbable vascular graft consider `` standard care '' , pediatric patient re-operated several time adjust prosthesis size somatic growth child associate substantial morbidity mortality require prolonged anticoagulation treatment , biodegradable polymer implant could represent `` one-time solution '' .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<criteria>1 . Patient require ECTCPC 2 . Male Female 3 . Aged ≥ 2 year 1 . Pulmonary artery pressure ( PAP ) &gt; 15 mm Hg exclude angiography/cardiac catheterization 2 . Pulmonary vascular resistance ( PVR ) &gt; 3 Wood unit exclude angiography/cardiac catheterization 3 . Moderate severe atrioventricular ( AV ) valve regurgitation require correction , determine echocardiography and/or angiography 4 . Moderate severe outflow valve regurgitation require correction determine echocardiography and/or angiography 5 . Outflow tract ( aortic arch isthmus ) obstruction exclude : residual outflow gradient ≥ 20mm Hg requirement corrective surgery determine echocardiography and/ angiography 6 . All arrhythmia determine ECG and/or investigator 's discretion 7 . Renal dysfunction exclude serum creatinine &gt; ULN and/or urea &gt; ULN and/or investigator 's discretion 8 . Hepatic dysfunction exclude ALT &gt; ULN , AST &gt; ULN , GGT &gt; ULN and/or investigator 's discretion 9 . Coagulation disorder define INR outside normal value , PTT &gt; ULN Fibrinogen &lt; LLN and/or investigator 's discretion 10 . Transcutaneous O2 saturation &lt; 65 % and/or investigator 's discretion 11 . Immunodeficiency 12 . Trisomia 21 13 . Asplenia determine abdominal ultrasound 14 . Heterotaxia determine abdominal ultrasound 15 . HIVinfection 16 . Syphilis ( Treponema pallidum ) 17 . HepatitisB and/or C virus infection 18 . Unwillingness Parental/legal guardian give consent 19 . Contraindications ethical ground 20 . Treatment investigational product 21 . Known suspected noncompliance , drug alcohol abuse parents/legal guardian 22 . Inability parents/legal guardian follow procedure study , e.g . due language problem 23 . Participation patient another study within 30 day precede present study 24 . Previous enrollment patient current study 25 . Enrollment investigator 's family member , employee dependent person</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>